(Q43912252)

English

Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial

scientific article published on January 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial (English)

1 reference

Europe PubMed Central

28 November 2017

Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial (English)

1 reference

10.1081/JAS-120018780

https://api.crossref.org/works/10.1081/JAS-120018780

18 March 2024

1 reference

based on heuristic

inferred from title

author name string

W. Pleskow

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529100

18 March 2024

C. F. LaForce

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529100

18 March 2024

U. Yegen

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529100

18 March 2024

D. Matos

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529100

18 March 2024

G. Della Cioppa

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529100

18 March 2024

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

28 November 2017

full work available at URL

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

1 reference

10.1081/JAS-120018780

https://api.crossref.org/works/10.1081/JAS-120018780

18 March 2024

Journal of Asthma

1 reference

Europe PubMed Central

28 November 2017

40

1 reference

Europe PubMed Central

28 November 2017

5

1 reference

Europe PubMed Central

28 November 2017

505-514

1 reference

Europe PubMed Central

28 November 2017

Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Why are long-acting beta-adrenoceptor agonists long-acting?

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Rapid onset of action of inhaled formoterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120018780

21 January 2018

Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients

20

1 reference

10.1081/JAS-120018780

https://api.crossref.org/works/10.1081/JAS-120018780

18 March 2024

Identifiers

10.1081/JAS-120018780

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43912252&oldid=2104730122"